TL-895 is under clinical development by Telios Pharma and currently in Phase II for Myelofibrosis. According to GlobalData, Phase II drugs for Myelofibrosis have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TL-895’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TL-895 overview
TL-895 is under development for the treatment of myelofibrosis, indolent systemic mastocytosis, chronic idiopathic myelofibrosis (primary myelofibrosis), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (Post-ET MF), small lymphocytic lymphoma (SLL) and relapsed/refractory chronic lymphocytic leukemia. It is administered by the oral route. The drug candidate targets brutons tyrosine kinase. The drug candidate is a new chemical entity. It was also under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cancer patients, waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), diffuse large B-cell lymphoma, follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL).
It was under development for the treatment of relapsed and refractory acute myeloid leukemia.
Telios Pharma overview
Telios Pharma is a biopharmaceutical company. It develops oral BTK inhibitors to treat patients suffering from inflammation and allergies. The company is headquartered in Redwood City, California, the US.
For a complete picture of TL-895’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
